Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Variability in Extracellular Vesicle Characterization Across Measurement Techniques.

Journal of extracellular biology·2026
Same author

Notch signaling regulates the secretion of pro-metastatic factors in extracellular vesicles in liposarcoma.

Cancer letters·2026
Same author

Clear Cell and Histiocytic/Dendritic Cell Sarcomas: Clinical Outcomes, Molecular Features, and Diagnostic Pitfalls.

Cancers·2026
Same author

Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing.

PloS one·2025
Same author

Oncogenic Functions of Alternatively Spliced <i>MDM2-ALT2</i> Isoform in Retroperitoneal Liposarcoma.

International journal of molecular sciences·2025
Same author

Three-dimensional models: from cell culture to Patient-Derived Organoid and its application to future liposarcoma research.

Oncology research·2024

Related Experiment Video

Updated: Mar 21, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.4K

Liposarcoma: molecular targets and therapeutic implications.

Kate Lynn J Bill1,2, Lucia Casadei1,2, Bethany C Prudner1,2

  • 1The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.

Cellular and Molecular Life Sciences : CMLS
|May 14, 2016
PubMed
Summary

Liposarcoma (LPS) is a common soft tissue cancer. This review explores actionable molecular markers in LPS to develop targeted therapies that improve treatment outcomes by selectively eliminating cancer cells.

Keywords:
12q13–15 ampliconsBiomarkerDedifferentiated liposarcomaExosomeMDM2Molecular-cytogenetic analysismiRNAs

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Related Experiment Videos

Last Updated: Mar 21, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Liposarcoma (LPS) represents the most frequent soft tissue sarcoma, comprising about 20% of adult sarcomas.
  • Current treatments like surgery, chemotherapy, and radiotherapy present significant limitations in efficacy and specificity.
  • A deeper understanding of the genetic and epigenetic alterations in LPS is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To review therapeutically actionable molecular markers in well-differentiated and dedifferentiated liposarcoma.
  • To highlight the potential clinical applicability of these molecular markers for targeted therapy development.

Main Methods:

  • Literature review of studies focusing on molecular alterations in liposarcoma.
  • Analysis of identified genetic and epigenetic deregulations.
  • Evaluation of the clinical relevance of molecular markers for targeted therapies.

Main Results:

  • Identification of several key molecular markers with therapeutic potential in LPS.
  • Discussion of the biological rationale for targeting these specific pathways.
  • Assessment of the potential for personalized medicine approaches in LPS treatment.

Conclusions:

  • Targeting specific molecular drivers in liposarcoma offers a promising avenue for improved therapeutic outcomes.
  • Biology-driven therapeutics could enhance treatment efficacy while minimizing toxicity to normal tissues.
  • Further research into molecular markers is essential for advancing liposarcoma treatment strategies.